Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022

SELL
$187.54 - $223.02 $43,509 - $51,740
-232 Closed
0 $0
Q1 2022

May 05, 2022

BUY
$193.77 - $244.14 $387 - $488
2 Added 0.87%
232 $49,000
Q4 2021

Feb 08, 2022

SELL
$223.92 - $287.77 $1,343 - $1,726
-6 Reduced 2.54%
230 $55,000
Q3 2021

Oct 27, 2021

BUY
$282.99 - $369.05 $1,697 - $2,214
6 Added 2.61%
236 $66,000
Q2 2021

Jul 21, 2021

SELL
$259.0 - $414.71 $17,871 - $28,614
-69 Reduced 23.08%
230 $79,000
Q4 2020

Jan 27, 2021

SELL
$236.26 - $355.63 $17,719 - $26,672
-75 Reduced 20.05%
299 $73,000
Q2 2020

Aug 04, 2020

SELL
$258.66 - $342.55 $3,879 - $5,138
-15 Reduced 3.86%
374 $100,000
Q1 2020

Apr 09, 2020

BUY
$268.85 - $341.04 $4,032 - $5,115
15 Added 4.01%
389 $123,000
Q4 2019

Jan 06, 2020

BUY
$220.06 - $304.07 $11,443 - $15,811
52 Added 16.15%
374 $111,000
Q3 2019

Oct 16, 2019

BUY
$217.44 - $243.88 $9,132 - $10,242
42 Added 15.0%
322 $75,000
Q2 2019

Aug 05, 2019

SELL
$219.29 - $241.72 $23,464 - $25,864
-107 Reduced 27.65%
280 $0
Q1 2019

Apr 16, 2019

SELL
$216.71 - $338.96 $14,952 - $23,388
-69 Reduced 15.13%
387 $91,000
Q4 2018

Jan 29, 2019

SELL
$278.5 - $352.75 $4,456 - $5,644
-16 Reduced 3.39%
456 $137,000
Q3 2018

Oct 29, 2018

BUY
$293.51 - $383.83 $6,750 - $8,828
23 Added 5.12%
472 $167,000
Q2 2018

Aug 10, 2018

SELL
$257.52 - $306.91 $44,035 - $52,481
-171 Reduced 27.58%
449 $130,000
Q1 2018

May 07, 2018

BUY
$260.13 - $367.91 $50,725 - $71,742
195 Added 45.88%
620 $170,000
Q4 2017

Feb 13, 2018

SELL
$307.64 - $344.58 $130,747 - $146,446
-425 Closed
0 $0
Q3 2017

Nov 06, 2017

BUY
$281.15 - $329.69 $54,824 - $64,289
195 Added 84.78%
425 $133,000
Q2 2017

Aug 11, 2017

BUY
N/A
230
230 $62,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Simon Quick Advisors, LLC Portfolio

Follow Simon Quick Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simon Quick Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simon Quick Advisors, LLC with notifications on news.